EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Psychedelic therapy and postpartum depression: priorities and prospects

Guillaume Thuery, Frank Crossen, Daniel Mc Loone, Catherine Hinds, Richard Duffy, Chaitra Jairaj, Andrew Harkin, John R Kelly iD

Therapeutic Advances in Psychopharmacology · 2026-03 · 16

DOI: 10.1177/20451253251408280 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 09.03.2026. Verfasst von Guillaume Thuery und 7 weiteren Autor:innen. Beteiligte Einrichtung: Trinity Institute of Neurosciences, Trinity College Dublin, Dublin, Ireland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: health research board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 15% of pregnant women experience postpartum depression (PPD). Even with currently available antidepressant treatments, many women will continue to be impaired by symptoms. Psychedelic therapy offers a promising transdiagnostic therapeutic strategy for several mental health disorders, and early results from current trials suggest that serotonergic psychedelics may represent a viable therapeutic approach for PPD. However, there is marked variability in the therapeutic response to psychedelic therapy, and the benefit–risk ratio in this population is not yet clear. To inform the rationale for the use of serotonergic psychedelics in the treatment of PPD, this review summarises the existing knowledge of immune, endocrine and neural pathways underpinning PPD and explores how serotonergic psychedelics interact with these pathways in the context of maternal motivation, bonding and caregiving behaviours. Finally, special considerations for psychedelic therapy in the postpartum period are outlined and future perspectives explored. Despite the rationale and encouraging early findings, further research is required to determine efficacy and safety profiles. Future studies, particularly longitudinal trials, should include adaptations and safeguards tailored to the unique physiological, psychological and caregiving contexts of the postpartum period.

Schlagwörter

Stichwörter der Autor:innen

5-MeO-DMTmajor depressionpostpartum depressionpsilocybinpsychedelics

Autor:innen und Institutionen

  • Trinity Institute of Neurosciences, Trinity College Dublin, Dublin, Ireland.
  • Psychedelic Research Group, Trinity College Dublin, Dublin, Ireland.
  • School of Medicine, Trinity College Dublin, Ireland.
  • The National Maternity Hospital, Dublin, Ireland.
  • School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
  • The Coombe Hospital, Dublin, Ireland.

ORCID-Profile: John R Kelly

Förderung

  • health research board

Zitieren

APA

Thuery, G., Crossen, F., Mc Loone, D., Hinds, C., Duffy, R., Jairaj, C., Harkin, A., & Kelly, J. R. (2026). Psychedelic therapy and postpartum depression: priorities and prospects. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253251408280

Vancouver

Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, et al. Psychedelic therapy and postpartum depression: priorities and prospects. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253251408280

BibTeX
@article{Thuery2026,
  author = {Thuery, Guillaume and Crossen, Frank and Mc Loone, Daniel and Hinds, Catherine and Duffy, Richard and Jairaj, Chaitra and Harkin, Andrew and Kelly, John R},
  title = {Psychedelic therapy and postpartum depression: priorities and prospects},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253251408280}
}
Kostenlos starten →